Ascletis Pharma Inc. (HKG:1672)
Hong Kong · Delayed Price · Currency is HKD 8.37
+0.07 (0.78%)
Sep 30, 2026, 4:08 PM HKT
Ascletis Pharma Employees
Ascletis Pharma had 217 employees as of June 30, 2026.
Employees
217
Change
n/a
Growth
n/a
Revenue / Employee
5.04K HKD
Profits / Employee
-3.15M HKD
Market Cap
8.77B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 217 | - | - |
| Dec 31, 2025 | 202 | -29 | -12.55% |
| Dec 31, 2024 | 231 | 12 | 5.48% |
| Dec 31, 2023 | 219 | -59 | -21.22% |
| Dec 31, 2022 | 278 | 12 | 4.51% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Employee RankingsAscletis Pharma News
- 1 day ago - Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis - PRNewsWire
- 23 days ago - Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs - PRNewsWire
- 4 weeks ago - Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management - PRNewsWire
- 2 months ago - Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model - PRNewsWire
- 2 months ago - Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30 - PRNewsWire
- 3 months ago - Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity - PRNewsWire
- 3 months ago - Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39 - PRNewsWire
- 4 months ago - Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026) - PRNewsWire